**Additional tables**

 **Additional table 1** ICD-10 codes for exclusion criteria

| **Diagnosis** | **Label** | **Hospitalisation** | **CD status** |
| --- | --- | --- | --- |
| Connective tissue diseases | Rheumatoid lung disease | J990 | – |
| Rheumatoid lung disease | M051 | – |
| Other necrotising vasculopathies | M31 | M31 |
| Systemic lupus erythematosus | M32 | M32 |
| Dermatopolymyositis | M33 | M33 |
| Systemic sclerosis | M34 | M34 |
| Other systemic involvement of connective tissue | M35 | M35 |
| Other localised connective tissue disorders | L94 | L94 |
| Pneumoconiosis | Coalworker pneumoconiosis | J60 | J60 |
| Pneumoconiosis due to asbestos and other mineral fibres | J61 | J61 |
| Pneumoconiosis due to dust containing silica | J62 | J62 |
| Pneumoconiosis due to other inorganic dust | J63 | J63 |
| Unspecified pneumoconiosis | J64 | J64 |
| Pneumoconiosis associated with tuberculosis | J65 | J65 |
| Airway disease due to specific organic dust | J66 | J66 |
| Hypersensitivity pneumonitis due to organic dust | J67 | J67 |
| Pleural plaque with presence of asbestos | J920 | – |
| Sarcoidosis | Sarcoidosis | D86 | D86 |
| Polyarteritis nodosa | Polyarteritis nodosa and related conditions | M30 | M30 |

 CD: chronic disease; ICD-10: 10th revision of the International Statistical Classification of Diseases and Related Health Problems.

 **Additional table 2** ICD-10 codes for acute respiratory-related hospitalisations (main diagnosis)

| **Diagnosis** | **Label** | **Hospitalisation** |
| --- | --- | --- |
| Legionnaires’ disease | Legionnaires’ disease | A481 |
| HIV disease resulting in infectious and parasitic diseases | HIV disease resulting in *Pneumocystis carinii* pneumonia | B206 |
| Cytomegaloviral pneumonitis | Cytomegaloviral pneumonitis | B250 |
| Pneumocystosis | Pneumocystosis | B59 |
| Influenza | Influenza due to identified zoonotic or pandemic influenza virus | J09 |
| Influenza due to identified seasonal influenza virus | J10 |
| Influenza, virus not identified | J11 |
| Pneumonia | Viral pneumonia, not classified elsewhere | J12 |
| Pneumonia due to *Streptococcus pneumoniae* | J13 |
| Pneumonia due to *Haemophilus influenzae* | J14 |
| Bacterial pneumonia not classified elsewhere | J15 |
| Pneumonia due to other infectious organisms not classified elsewhere | J16 |
| Pneumonia in diseases classified elsewhere | J17 |
| Pneumonia, organism unspecified | J18 |
| Bronchitis (not specified as acute or chronic) | Bronchitis not specified as acute or chronic | J40 |
| Bronchitis | Acute bronchitis | J20 |
| Acute bronchiolitis | Acute bronchiolitis | J21 |
| Unspecified acute lower respiratory infection | Unspecified acute lower respiratory infection | J22 |
| Other interstitial pulmonary diseases with fibrosis | Other interstitial pulmonary diseases with fibrosis | J841 |
| Pneumothorax | Pneumothorax | J93 |
| Acute respiratory failure | Acute respiratory failure  | J960 |
| Chronic respiratory failure | Chronic respiratory failure | J961  |
| Unspecified respiratory failure  | Respiratory failure, unspecified | J969 |

HIV: human immunodeficiency virus; ICD-10: 10th revision of the International Statistical Classification of Diseases and Related Health Problems.

 **Additional table 3** Unadjusted incidence rates and cumulative incidence of mortality in patients newly treated in 2016 with antifibrotic drugs

|  | ***PirfenidoneN = 291*** | ***NintedanibN = 423*** |
| --- | --- | --- |
| **Number of patients with event (%)** |
| Overall | 23 (7.9%) | 45 (10.6%) |
| **Duration between index date and event (in days)\*** |
| Mean (Std) | 201.9 (189.6) | 267.2 (164.1) |
| Median (IQR) | 121.0 (45.0 - 322.0) | 241.0 (122.0 - 372.0) |
| Min - Max | 9.0 - 619.0 | 14.0 - 651.0 |
| **Total person-years of the at risk population** | 226.1 | 365.1 |
| **Unajusted incidence rate [95% CI] (per 100 person-years)** | 10.17 [6.76 - 15.30] | 12.32 [9.20 - 16.51] |
| **Cumulative incidence of event [95% CI]** |
| 1 year | 9.07% [5.46% - 13.80%] | 11.36% [7.97% - 15.41%] |
| 1.5 year | 13.70% [8.40% - 20.29%] | 19.27% [13.70% - 25.55%] |
| 2 years | 16.40% [9.48% - 24.97%] | 24.23% [15.66% - 33.84%] |

The mean age of patients included in 2016 was similar in both groups (74.0 years (SD=7.9) in the pirfenidone group versus 72.9 years (SD=8.1) in the nintedanib group), as well as the median age (75 years versus 74 years).

**Additional figure 1** Comparison of overall mortality in patients newly treated in 2016 with pirfenidone or nintedanib

